BB Biotech AG
BBAGF
Other OTC55.00
USD
-21.06
- -
ISIN
CH0038389992
Return %
Stock
S&P500
1Y
0.13
19.01
3Y
-27.69
65.48
5Y
-27.69
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Daniel Koller
- Full Time Employees
- 10
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Seestrasse 16 Kusnacht Switzerland 8700
- IPO Date
- Oct 12, 2015
- Website
- bbbiotech.ch
- Similar Companies
- Business
- BB Biotech AG (Ticker: BBAGF) is a Switzerland-based investment company focused on publicly listed biotechnology firms developing and commercializing innovative drugs in areas such as oncology, neurological disorders, orphan diseases, metabolic diseases, cardiovascular conditions, infectious diseases, autoimmune diseases, and emerging technologies including RNA platforms, cell therapies, and gene therapies. The company maintains a concentrated portfolio of 20 to 35 holdings, with major positions as of December 31, 2024, including Argenx (13.7%), Ionis Pharmaceuticals (10.0%), Neurocrine Biosciences (9.4%), Intra-Cellular Therapies (7.6%), Revolution Medicines (7.2%), Vertex Pharmaceuticals (7.2%), Alnylam Pharmaceuticals (6.7%), and Incyte (5.6%); it targets mid- and small-cap biotech companies offering substantial therapeutic and economic potential while incorporating ESG criteria in its investment decisions. Shares trade on the SIX Swiss Exchange and Frankfurt Stock Exchange, providing investors access to this high-growth sector. Founded in 1993 and headquartered in Schaffhausen, Switzerland, BB Biotech AG operates globally with a focus on U.S.-centric investments given the concentration of biotech innovation there, supplemented by opportunities in Europe and other regions. Recent strategic developments include an ongoing portfolio reallocation announced in October 2024 to sharpen focus amid market volatility, which progressed into 2025 with Q1 results reflecting heightened concentration on high-conviction holdings; in November 2024, the company increased its stake in Molecular Templates Inc. by acquiring 156,424 shares at $0.61 each, bringing total ownership to 904,001 shares to bolster exposure to innovative cancer therapies. In July 2024, BB Biotech appointed a new head of its investment management team to support evolving market dynamics. The company reported strong financial performance in 2025, including a CHF 106 million net profit for the first nine months (as of October 2025), portfolio outperformance versus the Nasdaq Biotech Index in Q2 and Q3 2025 driven by sector recovery signals, and inclusion in the SPI ESG Index in September 2025; it also published its 2024 Annual Report in February 2025, proposing a dividend and positioning for structural biotech recovery.